Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers.

Cullberg M, Arfvidsson C, Larsson B, Malmgren A, Mitchell P, Wählby Hamrén U, Wray H.

Drugs R D. 2018 Jun;18(2):149-159. doi: 10.1007/s40268-018-0236-x.

2.

The impact of loading approach and biological activity on NOM removal by ion exchange resins.

Winter J, Wray HE, Schulz M, Vortisch R, Barbeau B, Bérubé PR.

Water Res. 2018 May 1;134:301-310. doi: 10.1016/j.watres.2018.01.052. Epub 2018 Feb 20.

PMID:
29433080
3.

Results from a drug utilization study of extended release quetiapine fumarate prescribed by psychiatrists as treatment for major depressive disorder in selected countries in the European Union.

Brody RS, Liss CL, Wray H, Kastango K, Bryant A, Fabre A, Thuresson A.

Int Clin Psychopharmacol. 2018 Mar;33(2):59-65. doi: 10.1097/YIC.0000000000000202.

4.

Effectiveness of a risk-minimization activity involving physician education on metabolic monitoring of patients receiving quetiapine: results from two postauthorization safety studies.

Brody RS, Liss CL, Wray H, Iovin R, Michaylira C, Muthutantri A, Damstetter P, Datto C, Jefferies L.

Int Clin Psychopharmacol. 2016 Jan;31(1):34-41. doi: 10.1097/YIC.0000000000000102.

PMID:
26451964
5.

A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.

De Soyza A, Pavord I, Elborn JS, Smith D, Wray H, Puu M, Larsson B, Stockley R.

Eur Respir J. 2015 Oct;46(4):1021-32. doi: 10.1183/13993003.00148-2015. Epub 2015 Sep 4.

6.

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.

Kirsten AM, Förster K, Radeczky E, Linnhoff A, Balint B, Watz H, Wray H, Salkeld L, Cullberg M, Larsson B.

Pulm Pharmacol Ther. 2015 Apr;31:36-41. doi: 10.1016/j.pupt.2015.02.001. Epub 2015 Feb 11.

PMID:
25681277
7.

The effect of tumour necrosis factor-α and insulin on equine digital blood vessel function in vitro.

Menzies-Gow NJ, Wray H, Bailey SR, Harris PA, Elliott J.

Inflamm Res. 2014 Aug;63(8):637-47. doi: 10.1007/s00011-014-0736-2. Epub 2014 Apr 24.

PMID:
24764104
8.

The effect of exercise on plasma concentrations of inflammatory markers in normal and previously laminitic ponies.

Menzies-Gow NJ, Wray H, Bailey SR, Harris PA, Elliott J.

Equine Vet J. 2014 May;46(3):317-21. doi: 10.1111/evj.12132. Epub 2013 Sep 11.

PMID:
23819851
9.

Plasma concentrations of inflammatory markers in previously laminitic ponies.

Wray H, Elliott J, Bailey SR, Harris PA, Menzies-Gow NJ.

Equine Vet J. 2013 Sep;45(5):546-51. doi: 10.1111/evj.12031. Epub 2013 Feb 19.

PMID:
23418944
10.

α6 Integrin and CD44 enrich for a primary keratinocyte population that displays resistance to UV-induced apoptosis.

Wray H, Mackenzie IC, Storey A, Navsaria H.

PLoS One. 2012;7(10):e46968. doi: 10.1371/journal.pone.0046968. Epub 2012 Oct 10.

11.

Effects of an oral MMP-9 and -12 inhibitor, AZD1236, on biomarkers in moderate/severe COPD: a randomised controlled trial.

Dahl R, Titlestad I, Lindqvist A, Wielders P, Wray H, Wang M, Samuelsson V, Mo J, Holt A.

Pulm Pharmacol Ther. 2012 Apr;25(2):169-77. doi: 10.1016/j.pupt.2011.12.011. Epub 2012 Feb 1.

PMID:
22306193
12.

Safety and tolerability of an oral MMP-9 and -12 inhibitor, AZD1236, in patients with moderate-to-severe COPD: a randomised controlled 6-week trial.

Magnussen H, Watz H, Kirsten A, Wang M, Wray H, Samuelsson V, Mo J, Kay R.

Pulm Pharmacol Ther. 2011 Oct;24(5):563-70. doi: 10.1016/j.pupt.2011.05.003. Epub 2011 May 23.

PMID:
21624491
13.
14.

The assessment of human regional drug absorption of free acid and sodium salt forms of acipimox, in healthy volunteers, to direct modified release formulation strategy.

Menon R, Cefali E, Wilding I, Wray H, Connor A.

Biopharm Drug Dispos. 2009 Dec;30(9):508-16. doi: 10.1002/bdd.683.

PMID:
19798634
15.

In vivo disintegration profiles of encapsulated and nonencapsulated sumatriptan: gamma scintigraphy in healthy volunteers.

Wilding IR, Clark D, Wray H, Alderman J, Muirhead N, Sikes CR.

J Clin Pharmacol. 2005 Jan;45(1):101-5.

PMID:
15601811
16.

Pharmacoscintigraphic comparison of HMR 1031, a VLA-4 antagonist, in healthy volunteers following delivery via a nebulizer and a dry powder inhaler.

Rohatagi S, Chapel S, Kirkesseli S, Newman S, Zhang J, Paccaly D, Randall L, Wray H, Wellington S, Shah B, Jensen BK.

Am J Ther. 2004 Mar-Apr;11(2):103-13.

PMID:
14999362
17.

Combined scintigraphic and pharmacokinetic investigation of enteric-coated mesalazine micropellets in healthy subjects.

Wilding IR, Behrens C, Tardif SJ, Wray H, Bias P, Albrecht W.

Aliment Pharmacol Ther. 2003 May 1;17(9):1153-62.

18.

Pharmacoscintigraphic assessment of the regional drug absorption of the dual angiotensin-converting enzyme/neutral endopeptidase inhibitor, M100240, in healthy volunteers.

Martin NE, Collison KR, Martin LL, Tardif S, Wilding I, Wray H, Barrett JS.

J Clin Pharmacol. 2003 May;43(5):529-38.

PMID:
12751274
19.
20.

Community PREP: the beginning of change.

Wray H.

Occup Health (Lond). 1995 Jul;47(7):234-7. No abstract available.

PMID:
7659398
21.

Optimal contrast enhancement of the liver using helical (spiral) CT: value of SmartPrep.

Silverman PM, Brown B, Wray H, Fox SH, Cooper C, Roberts S, Zeman RK.

AJR Am J Roentgenol. 1995 May;164(5):1169-71. No abstract available.

PMID:
7717226
22.

Adrenal insufficiency in a man with non-classical 21-hydroxylase deficiency: consequence or coincidence?

Glass AR, Jackson SG, Perlstein RS, Wray HL.

J Endocrinol Invest. 1994 Sep;17(8):665-70.

PMID:
7868807
23.

Guidelines for conducting HIV research with human subjects at a U.S. military medical center.

Marks ES, Derderian SS, Wray HL.

IRB. 1992 Jan-Feb;14(1):7-10. No abstract available.

PMID:
11652042
24.

Comparative assessment of a new breath-actuated inhaler in patients with reversible airways obstruction.

Waterhouse JC, Simmons JL, Wray H, Howard P.

Respiration. 1992;59(3):155-8.

PMID:
1439226
25.

In vitro dissolution of calcium carbonate preparations.

Brennan MJ, Duncan WE, Wartofsky L, Butler VM, Wray HL.

Calcif Tissue Int. 1991 Nov;49(5):308-12.

PMID:
1782571
26.

Estrogen regulation of the nuclear 1,25-dihydroxyvitamin D3 receptor in rat liver and kidney.

Duncan WE, Glass AR, Wray HL.

Endocrinology. 1991 Nov;129(5):2318-24.

PMID:
1657571
27.

Identification and partial characterization of multiple forms of biologically active EGF in rat milk.

Schaudies RP, Grimes J, Wray HL, Koldovský O.

Am J Physiol. 1990 Dec;259(6 Pt 1):G1056-61.

PMID:
2260661
28.

Intracellular processing of epidermal growth factor by early wound healing cells.

Seyfer AE, Nassaux P, Emory R, Wray HL, Schaudies RP.

Surgery. 1990 Jan;107(1):69-73.

PMID:
2404350
29.

The effects of lactation on bone mineral content in healthy postpartum women.

Hayslip CC, Klein TA, Wray HL, Duncan WE.

Obstet Gynecol. 1989 Apr;73(4):588-92.

PMID:
2927853
30.

[Flecainide (Tambocor)--a new anti-arrhythmia agent].

Wray H, Corbey M.

Tidsskr Nor Laegeforen. 1989 Jan 10;109(1):92-4. Norwegian. No abstract available.

PMID:
2492125
31.

A 1,25-dihydroxyvitamin D3 receptor-like protein in mammalian and avian liver nuclei.

Duncan WE, Whitehead D, Wray HL.

Endocrinology. 1988 Jun;122(6):2584-9.

PMID:
2836167
32.

Inhibition of EGF processing in responsive and nonresponsive human fibroblasts.

Schaudies RP, Wray HL.

J Cell Physiol. 1988 Apr;135(1):79-86.

PMID:
3259239
33.

25-Hydroxyvitamin D2 and 25-hydroxyvitamin D3 as measured by liquid chromatography and by competitive protein binding.

Bruton J, Wray HL, Dawson E, Butler V.

Clin Chem. 1985 May;31(5):783-4. No abstract available.

34.

Early management of hypercalcemic crisis: case report and literature review.

Baker JR, Wray HL.

Mil Med. 1982 Sep;147(9):756-60. No abstract available.

PMID:
6217430
35.
36.

Pregnancy in the Turner syndrome with only 45,X chromosomal constitution.

Wray HL, Freeman MV, Ming PM.

Fertil Steril. 1981 May;35(5):509-14.

PMID:
7227566
37.

Urinary cyclic AMP during surgery for primary hyperparathyroidism.

Wray HL, Monchik JM, Earll JM.

N Engl J Med. 1981 Apr 9;304(15):912-4. No abstract available.

PMID:
6259527
38.

Effect of 3,5,3'-triiodothyronine and 3,3',5'-triiodothyronine administration on serum tri-, di-, and monoiodothyronines and plasma cyclic nucleotides in sheep.

Wray HL, Burman KD, Smallridge RC, Alford JP, Butler VM, Wright FD, Wartofsky L.

Endocrinology. 1980 Jul;107(1):130-6. No abstract available.

PMID:
6247133
39.

Skeletal responsiveness in pseudohypoparathyroidism. A spectrum of clinical disease.

Kidd GS, Schaaf M, Adler RA, Lassman MN, Wray HL.

Am J Med. 1980 May;68(5):772-81.

PMID:
6246800
40.

Changes in brain levels of cyclic nucleotides and gamma-aminobutyric acid in barbiturate dependence and withdrawal.

Lenox RH, Wray HL, Kant GJ, Hawkins TD, Meyerhoff JL.

Eur J Pharmacol. 1979 Apr 15;55(2):159-69.

PMID:
222596
41.

Cyclic nucleotides and growth regulation in suspension cultures of mammalian cells.

Wray HL, Glinos AD.

Am J Physiol. 1978 May;234(5):C131-8. No abstract available.

PMID:
206153
42.

Regional levels of cyclic AMP in rat brain: pitfalls of microwave inactivation.

Lenox RH, Meyerhoff JL, Gandhi OP, Wray HL.

J Cyclic Nucleotide Res. 1977 Oct;3(5):367-79.

PMID:
201684
43.

Cyclic AMP stimulation of membrane phosphorylation and Ca2+-activated, Mg2+-dependent ATPase in cardiac sarcoplasmic reticulum.

Wray HL, Gray RR.

Biochim Biophys Acta. 1977 Sep 14;461(3):441-59. No abstract available.

PMID:
197994
44.

Immunofluorescent localization of cyclic AMP in developing rat testis.

MacIndoe JH, Sullivan W, Wray HL.

Endocrinology. 1977 Aug;101(2):568-76. No abstract available.

PMID:
195799
45.

Nonautonomy of parathyroid hormone and urinary cyclic AMP in primary hyperparathyroidism.

Monchik JM, Wray HL, Schaaf M, Earll JM.

Am J Surg. 1977 Apr;133(4):498-505.

PMID:
192097
46.

Experimental induction of hypoparathyroidism with parathyroid hormone antibodies.

Monchik JM, Gemma FE, Bond H, Wray HL.

Am J Surg. 1976 Apr;131(4):471-5.

PMID:
178246
47.

Statistical characterization of the random errors in the radioimmunoassay dose--response variable.

Rodbard D, Lenox RH, Wray HL, Ramseth D.

Clin Chem. 1976 Mar;22(3):350-8.

PMID:
175978
48.

Adenosine 3', 5'-monophosphate-dependent protein kinase in adipose tissue: inhibition by tolbutamide.

Wray HL, Harris AW.

Biochem Biophys Res Commun. 1973 Jul 2;53(1):291-4. No abstract available.

PMID:
4354934
49.

Cyclic adenosine 3',5'-monophosphate-stimulated protein kinase and a substrate associated with cardiac sarcoplasmic reticulum.

Wray HL, Gray RR, Olsson RA.

J Biol Chem. 1973 Feb 25;248(4):1496-8. No abstract available.

50.

A critical appraisal of the circulation time test.

Selzer A, Dunlap RW, Wray HW, Russell J.

Arch Intern Med. 1968 Dec;122(6):491-5. No abstract available.

PMID:
5721875

Supplemental Content

Support Center